Industry Strength Score
36/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
INFLARX NV (IFRX) Stock Price & Overview
NASDAQ:IFRX • NL0012661870
Current stock price
2.1 USD
+0.03 (+1.45%)
At close:
2.05 USD
-0.05 (-2.38%)
After Hours:
The current stock price of IFRX is 2.1 USD. Today IFRX is up by 1.45%. In the past month the price increased by 130.16%. In the past year, price increased by 21.39%.
IFRX Key Statistics
52-Week Range0.7113 - 2.195
Current IFRX stock price positioned within its 52-week range.
1-Month Range0.9002 - 2.195
Current IFRX stock price positioned within its 1-month range.
- Market Cap
- 151.809M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.78
- Dividend Yield
- N/A
IFRX Stock Performance
Today
+1.45%
1 Week
+41.89%
1 Month
+130.16%
3 Months
+138.07%
Longer-term
6 Months +43.84%
1 Year +21.39%
2 Years +46.85%
3 Years -49.88%
5 Years -31.15%
10 Years N/A
IFRX Stock Chart
IFRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IFRX. When comparing the yearly performance of all stocks, IFRX is one of the better performing stocks in the market, outperforming 94.26% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
IFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IFRX. IFRX may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IFRX Earnings
On March 19, 2026 IFRX reported an EPS of -0.15 and a revenue of -34.00K. The company beat EPS expectations (1.96% surprise) and missed revenue expectations (-128.81% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateMar 19, 2026
PeriodQ4 / 2025
EPS Reported-€0.15
Revenue Reported-34K
EPS Surprise 1.96%
Revenue Surprise -128.81%
IFRX Forecast & Estimates
14 analysts have analysed IFRX and the average price target is 8.74 USD. This implies a price increase of 316.33% is expected in the next year compared to the current price of 2.1.
For the next year, analysts expect an EPS growth of 25.15% and a revenue growth -75.98% for IFRX
Analysts
Analysts81.43
Price Target8.74 (316.19%)
EPS Next Y25.15%
Revenue Next Year-75.98%
IFRX Financial Highlights
Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.78. The EPS increased by 15.19% compared to the year before.
Income Statements
Revenue(TTM)29.30K
Net Income(TTM)-40.10M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.55% | ||
| ROE | -88.4% | ||
| Debt/Equity | 0.02 |
Chartmill High Growth Momentum
EPS Q2Q%-87.5%
Sales Q2Q%-3300%
EPS 1Y (TTM)15.19%
Revenue 1Y (TTM)-82.33%
IFRX Ownership
Ownership
Inst Owners27.25%
Shares72.29M
Float67.97M
Ins Owners5.97%
Short Float %2.66%
Short Ratio2.85
IFRX Industry Overview
IFRX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 52 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
78/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
21%
Outperformed 21% of sub-industries
3 Month Rank
21%
Outperformed 21% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 52
- New Highs
- 1.9%
- New Lows
- 11.5%
- Average ROE
- 26.9%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 26.1%
- Average P/E
- 38.5
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
IFRX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IFRX
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Company Info
IPO: 2017-11-08
INFLARX NV
Winzerlaer Str. 2
Jena THUERINGEN 07745 DE
CEO: Niels Riedemann
Employees: 74
Phone: 493641508180
INFLARX NV / IFRX FAQ
Can you describe the business of INFLARX NV?
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
What is the stock price of INFLARX NV today?
The current stock price of IFRX is 2.1 USD. The price increased by 1.45% in the last trading session.
Does IFRX stock pay dividends?
IFRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IFRX stock?
IFRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for INFLARX NV?
INFLARX NV (IFRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for IFRX stock?
INFLARX NV (IFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.78).